Repligen Co. (NASDAQ:RGEN) Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC boosted its position in Repligen Co. (NASDAQ:RGEN) by 15.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 684 shares of the biotechnology company’s stock after acquiring an additional 90 shares during the quarter. GAMMA Investing LLC’s holdings in Repligen were worth $98,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in RGEN. Champlain Investment Partners LLC raised its position in Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after purchasing an additional 850,345 shares during the period. Thrivent Financial for Lutherans increased its position in shares of Repligen by 240.5% during the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock worth $75,866,000 after acquiring an additional 425,061 shares during the last quarter. DF Dent & Co. Inc. increased its position in shares of Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after acquiring an additional 139,615 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Repligen by 39.4% during the second quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock worth $54,149,000 after acquiring an additional 121,305 shares during the last quarter. Finally, Two Sigma Advisers LP increased its position in shares of Repligen by 421.9% during the third quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock worth $18,796,000 after acquiring an additional 102,100 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on RGEN shares. Canaccord Genuity Group started coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Wolfe Research assumed coverage on Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Finally, StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and an average price target of $185.20.

Repligen Trading Up 0.1 %

Shares of NASDAQ:RGEN opened at $154.86 on Friday. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13. The firm has a fifty day moving average price of $146.77 and a 200 day moving average price of $143.29. The stock has a market capitalization of $8.68 billion, a PE ratio of -418.53, a P/E/G ratio of 4.64 and a beta of 0.97.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same period in the prior year, the company earned $0.23 earnings per share. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. Analysts expect that Repligen Co. will post 1.54 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.